Myelofibrosis (PMF) Clinical Trials

6 recruitingLast updated: May 13, 2026

There are 6 actively recruiting myelofibrosis (pmf) clinical trials across 4 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include New York, New York, United States, Buffalo, New York, United States, Chūō, Yamanashi, Japan. Updated daily from ClinicalTrials.gov.


Myelofibrosis (PMF) Trials at a Glance

6 actively recruiting trials for myelofibrosis (pmf) are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in New York, Buffalo, and Chūō. Lead sponsors running myelofibrosis (pmf) studies include Novartis Pharmaceuticals, Icahn School of Medicine at Mount Sinai, and MPN Research Foundation.

Browse myelofibrosis (pmf) trials by phase

Treatments under study

About Myelofibrosis (PMF) Clinical Trials

Looking for clinical trials for Myelofibrosis (PMF)? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelofibrosis (PMF) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelofibrosis (PMF) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 3

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals460 enrolled5 locationsNCT07357727
Recruiting
Phase 2

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Icahn School of Medicine at Mount Sinai10 enrolled9 locationsNCT05835466
Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Primary myelofibrosis (PMF)Post-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Prelude Therapeutics100 enrolled1 locationNCT07469891
Recruiting
Phase 1

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Primary myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (Post-PV MF)Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Novartis Pharmaceuticals6 enrolled6 locationsNCT07340138
Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Primary myelofibrosis (PMF)Myeloproliferative DisordersMyelofibrosis+49 more
MPN Research Foundation5,000 enrolled2 locationsNCT07362225
Recruiting
Phase 2

Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

Primary myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
The University of Hong Kong20 enrolled1 locationNCT06770842